Jun 2026 (Q2 FY26) — Aug 6, 2026
CytomX Q2 FY26 — Varseta-M Pipeline Broadens with New GI Cancer Cohorts and Combination Studies
Read the full callCytomX (CTMX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
CytomX earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1.4 | −92.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -1677.1 | −1670.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -20.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.41 +8.07% · +$0.18
Performance −29.5% 1Y
1Y: $3.42 on 14 Oct 2025 → $2.41. High $6.75 (16 Mar 2026), low $2.23 (14 Oct 2026).
- Previous close
- $2.23
- 52-week range
- $2.23 – $6.75
- One year
- −29.33%
Overview
- Symbol
- CTMX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
CytomX earnings calls (CTMX)
Financials
What the filings say
Net profit, year on year: −13319% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 38 | 51 | 19 | 6 | 1 | 10 | 1 |
| Operating profit | 4 | 18 | 23 | -1 | -16 | -28 | -20 | -24 |
| Operating margin | 12.3% | 46.4% | 44.4% | −6.9% | −264.4% | −4212.8% | −191.8% | −1677.1% |
| Profit before tax | 6 | 19 | 24 | -0 | -14 | -26 | -18 | -21 |
| Tax rate | 1.1% | 0.3% | 0.3% | −69.2% | −0.4% | −0.2% | −0.3% | −0.3% |
| Net profit | 6 | 19 | 24 | -0 | -14 | -27 | -18 | -21 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -315 | -443 | -508 | -624 | -723 | -723 | -692 | -712 |
| Total liabilities | 326 | 290 | 366 | 340 | 347 | 249 | 121 | 53 |
| Fixed assets | 7 | 7 | 7 | 6 | 5 | 4 | 2 | 1 |
| Total assets | 457 | 341 | 359 | 339 | 261 | 202 | 121 | 152 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -76 | -140 | 5 | -119 | -111 | -56 | -86 | -76 |
| Cash from investing | 6 | 80 | -19 | 22 | 98 | -151 | 100 | -60 |
| Cash from financing | 140 | 2 | 17 | 110 | 1 | 30 | 8 | 110 |
| Capital expenditure | -4 | -3 | -2 | -2 | -2 | -1 | -0 | -0 |
| Free cash flow | -79 | -144 | 3 | -121 | -113 | -57 | -87 | -76 |
Insider filings
12 filings between Nov 6, 2025 and Aug 3, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$1.69M
6 sales by 4 insiders
33% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 6
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| McCarthy Sean A. | — | $1.23M | Mar 17, 2026 |
| BELVIN MARCIA | — | $202.3K | Mar 17, 2026 |
| Chu Yu-Waye | — | $136.7K | Mar 17, 2026 |
| Ogden Christopher | — | $129.1K | Jun 15, 2026 |
Latest filings (32)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 3, 2026 | Carvajal Alejandra Chief Legal Officer | Award | 100,000 | $0 |
| Jun 15, 2026 | Ogden Christopher Chief Financial Officer | Sale | 1,624 | $5.0K |
| Mar 17, 2026 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 31,492 | $202.3K |
| Mar 17, 2026 | Ogden Christopher Chief Financial Officer | Sale | 19,323 | $124.1K |
| Mar 17, 2026 | McCarthy Sean A. CEO | Sale 10b5-1 plan | 118,969 | $764.1K |
| Mar 17, 2026 | Chu Yu-Waye Chief Medical Officer | Sale | 21,279 | $136.7K |
| Feb 2, 2026 | Ogden Christopher Chief Financial Officer | Award | 90,000 | $0 |
| Feb 2, 2026 | McCarthy Sean A. CEO | Award | 210,000 | $0 |
| Feb 2, 2026 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 60,000 | $0 |
| Feb 2, 2026 | Chu Yu-Waye Chief Medical Officer | Award | 75,000 | $0 |
| Feb 2, 2026 | Lester Rachael Chief Business Officer | Award | 20,000 | $0 |
| Nov 6, 2025 | McCarthy Sean A. CEO | Sale 10b5-1 plan | 101,793 | $461.9K |
| Jun 16, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 13,884 | $37.3K |
| Jun 16, 2025 | McCarthy Sean A. CEO | Sale | 55,511 | $149.3K |
| Jun 16, 2025 | Ogden Christopher Chief Financial Officer | Sale | 10,614 | $28.5K |
| Jun 13, 2025 | Ogden Christopher Chief Financial Officer | Sale | 1,641 | $4.8K |
| Jun 13, 2025 | McCarthy Sean A. CEO | Option exercise | 150,000 | $0 |
| Jun 13, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Option exercise | 37,500 | $0 |
| Jun 13, 2025 | Ogden Christopher Chief Financial Officer | Option exercise | 37,500 | $0 |
| Mar 18, 2025 | McCarthy Sean A. CEO | Sale | 37,656 | $22.6K |
| Mar 18, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 19,512 | $11.7K |
| Mar 18, 2025 | ROWLAND LLOYD A General Counsel | Sale | 10,203 | $6.1K |
| Mar 18, 2025 | Chu Yu-Waye Chief Medical Officer | Sale | 4,025 | $2.4K |
| Mar 18, 2025 | Ogden Christopher Chief Financial Officer | Sale | 8,551 | $5.1K |
| Feb 4, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 35,000 | $0 |
| Feb 4, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 57,500 | $0 |
| Feb 4, 2025 | McCarthy Sean A. CEO | Award | 180,000 | $0 |
| Feb 4, 2025 | McCarthy Sean A. CEO | Award | 195,000 | $0 |
| Feb 4, 2025 | Ogden Christopher Chief Financial Officer | Award | 44,000 | $0 |
| Feb 4, 2025 | Ogden Christopher Chief Financial Officer | Award | 57,500 | $0 |
| Feb 4, 2025 | Chu Yu-Waye Chief Medical Officer | Award | 56,000 | $0 |
| Feb 4, 2025 | Chu Yu-Waye Chief Medical Officer | Award | 57,500 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CytomX Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow CytomX Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading